Finance
Finance
HomeNVZMF • OTCMKTS
Novozymes A/S
$62.46
Aug 22, 8:10:00 PM GMT-4 · USD · OTCMKTS · Disclaimer
StockUS listed security
Previous close
$61.49
Day range
$62.46 - $62.46
Year range
$53.55 - $75.97
Market cap
166.13B DKK
Avg Volume
345.00
P/E ratio
-
Dividend yield
-
Primary exchange
CPH
In the news
Financials
Income Statement
Revenue
Net income
(EUR)Jun 2025Y/Y change
Revenue
1.02B4.12%
Operating expense
324.70M11.16%
Net income
136.80M347.06%
Net profit margin
13.43329.07%
Earnings per share
2.69
EBITDA
356.40M45.59%
Effective tax rate
21.60%
Total assets
Total liabilities
(EUR)Jun 2025Y/Y change
Cash and short-term investments
328.20M25.84%
Total assets
16.40B7.53%
Total liabilities
5.66B33.22%
Total equity
10.74B
Shares outstanding
465.60M
Price to book
2.67
Return on assets
3.49%
Return on capital
4.07%
Net change in cash
(EUR)Jun 2025Y/Y change
Net income
136.80M347.06%
Cash from operations
320.10M-8.96%
Cash from investing
-1.54B-6,217.21%
Cash from financing
1.31B561.87%
Net change in cash
78.70M63.96%
Free cash flow
238.46M
About
Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024. Prior to the merger, the company had operations around the world, including in China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Class B shares of its stock were listed on the NASDAQ OMX Nordic exchange. Wikipedia
Founded
2000
Employees
10,582
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu